Psilocybin Therapy for Depression in Serious Illnesses

We are studying whether medium/high doses of psilocybin can help reduce depression and anxiety in patients with COPD, ALS, MS, or APD. This research aims to improve their quality of life and support their caregivers.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Psilocybin

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Narodni Ustav Dusevniho Zdravi
Psychedelic research centre
Roztoky, Czechia
Region Hovedstaden
Neurology
Frederiksberg, Denmark
Universitair Medisch Centrum Groningen
Psychiatry
Groningen, Netherlands

Sponsor: Universitair Medisch Centrum Groningen
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.